Camallergyalso Known As Cambridge Allergy Ltdis A Biopharmaceutical Company Founded In 2015 And Based In Cambridgeukthe Company Specializes In Developing Innovative Treatments For Food Allergieswith A Strong Focus On Peanut Allergiesits Flagship Productca002Is An Oral Immunotherapy Designed To Provide Protection Against Peanut Allergies Within 14 Weeks Of Therapythe Treatment Has Shown Promising Results In Phase 2 Trials Involving Over 300 Children Camallergy Operates A Cgmp Certified Manufacturing Facility In The Ukensuring Compliance With Us And Eu Regulations For The Production Of Ca002The Company Is Currently Conducting Phase 3 Clinical Trialshaving Received Fda Acceptance For Its Investigational New Drug Applicationin 2023Camallergy Partnered With Ondosis To Enhance Its Treatment Delivery Through A Specialized Dosage Manager Devicewhich Allows For Precise Dosing During The Therapy Processwith A Market Valued At Approximately $1 7 Billioncamallergy Is Positioned As A Leader In Peanut Allergy Immunotherapy
